Is amnestic mild cognitive impairment a neuro-immune condition?

BackgroundThe pathophysiology of amnestic Mild Cognitive Impairment (aMCI) is largely unknown, although some papers found signs of immune activation. AimsTo assess the cytokine network in aMCI after excluding patients with major depression (MDD) and to examine the immune profiles of quantitative aMCI (qMCI) and distress symptoms of old age (DSOA) scores. MethodsA cross-sectional study was conducted on 61 Thai aMCI participants and 60 healthy old adults (both without MDD). The Bio-Plex Pro human cytokine 27-plex test kit and LUMINEX 200 were used to assay cytokines/chemokines/growth factors in fasting plasma samples. ResultsaMCI is characterized by significant general immnosuppression, and reductions in T helper 1 (Th)1 and T cell growth profiles, the immune-inflammatory responses system, interleukin (IL)1{beta}, IL6, IL7, IL12p70, IL13, GM-CSF, and MCP-1 as compared with controls. These 7 cytokines/chemokines exhibit neuroprotective effects at physiologic concentrations. In multivariate analyses, three neurotoxic chemokines, CCL11, CCL5, and CXCL8, emerged as significant predictors of aMCI. Logistic regression showed that aMCI was best predicted by combining IL7, IL1{beta}, MCP-1, years of education (all inversely associated) and CCL5 (positively associated). We found that 38.2% of the variance in the qMCI score was explained by IL7, IL1{beta}, MCP-1, IL13, years of education (inversely associated) and CCL5 (positively associated). The DSOA were not associated with any immune data. DiscussionA dysbalance between lowered levels of neuroprotective cytokines and chemokines, and relative increases in neurotoxic chemokines are key factors in aMCI. Future MCI research should always control for the confounding effects of affective symptoms.